

ONLINE SUPPLEMENTARY DATA

Supplementary Table 1. Treatment-related damage. Univariable and multivariable binary logistic regression analysis of treatment related vasculitis damage index (VDI) items at two years.

Variable	Univariable analysis		Multivariable analysis ¹	
	OR (95% CI)	P value	OR (95% CI)	P value
Age (per year)	0.99 (0.86-1.14)	0.84	1.05 (0.89-1.24)	0.58
Male sex	0.76 (0.31-1.87)	0.56	0.77 (0.27-2.19)	0.63
BVAS (per point) ²	1.05 (0.97-1.13)	0.22	1.02 (0.92-1.13)	0.75
MPO/P-ANCA	0.54 (0.22-1.33)	0.18	0.92 (0.27-3.09)	0.89
CRP (per percentile) ³	1.18 (0.89-1.57)	0.26	1.04 (0.74-1.48)	0.81
Creatinine (per percentile) ⁴	0.89 (0.67-1.19)	0.45	0.86 (0.60-1.23)	0.40
Comorbidity score (per point)	1.34 (0.76-2.35)	0.32	1.58 (0.81-3.06)	0.18
CYC/RTX	0.71 (0.20-2.56)	0.60	0.28 (0.055-1.41)	0.12
Prednisolone dose (per percentile)	1.19 (0.90-1.57)	0.22	1.25 (0.88-1.77)	0.21
Methylprednisolone dose (per 250 mg)	1.14 (0.97-1.35)	0.11	1.25 (1.01-1.55)	0.043

Analysis of 104 patients with complete treatment data and data on treatment-related damage.
OR, odds ratio; CI, confidence interval; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; P-ANCA, perinuclear anti-neutrophil cytoplasmic antibodies; CRP, C-reactive protein; CYC/RTX, ≥ 2000 mg oral cyclophosphamide/ ≥ 1500 mg intravenous cyclophosphamide or rituximab

¹Multivariable analysis performed on 96 patients ²Data missing in two patients ³Data missing in five patients ⁴Data missing in two patients

Supplementary Table 2. Outcome variables. Frequency and distribution of organ damage, hospitalization, and deaths caused by infection in the three participating countries.

	Czech Republic	Sweden	United Kingdom	P value
VDI score 1 year ¹	3 (2-4)	2 (1-3)	1 (1-2)	0.001
VDI score 2 years ²	3 (2-4)	2 (2-3)	1 (1-2)	0.003
Treatment-related damage 1 year ³	33.3% (6/18)	21.3% (16/75)	12.5% (3/24)	0.27
Treatment-related damage 2 years ⁴	37.5% (6/16)	28.4% (19/67)	14.3% (3/21)	0.26
Rehospitalization ⁵	83.3% (30/36)	68.6% (70/102)	51.9% (14/27)	0.028
Total hospital time (days) ⁶	36 (17-53)	29 (17-48)	34 (16-42)	0.40
Death caused by infection ⁷	36.4% (8/22)	21.6% (8/37)	30.0% (3/10)	0.46

Values are presented as % (n) or median (interquartile range) and exclude missing data.

VDI, Vasculitis damage index

¹Data on 121 patients ²Data on 108 patients ³Data on 117 patients ⁴Data on 104 patients ⁵Data on 165 patients ⁶Data on 151 patients ⁷Data on 69 patients who died during study period

Supplementary Table 3. Total hospital time. Univariable and multivariable linear regression analysis of cumulative number of days admitted to hospital during the first year after diagnosis.

Variable	Univariable analysis		Multivariable analysis ¹	
	β (95% CI)	P value	β (95% CI)	P value
Age (per year)	0.076 (-1.48-1.63)	0.92	-0.40 (-2.19-1.39)	0.66
Male sex	-0.52 (-11.99-10.96)	0.93	-2.09 (-14.83-10.66)	0.75
BVAS (per point) ²	1.33 (0.31-2.35)	0.011	0.74 (-0.48-1.95)	0.23
MPO-ANCA	-5.19 (-17.39-7.01)	0.40	-6.78 (-21.36-7.81)	0.36
CRP (per percentile) ³	2.57 (-1.18-6.31)	0.18	3.00 (-1.41-7.41)	0.18
Creatinine (per percentile) ⁴	3.17 (-0.48-6.83)	0.088	5.04 (0.67-9.41)	0.024
Comorbidity score (per point)	0.95 (-6.24-8.15)	0.79	-0.22 (-8.27-7.84)	0.96
CYC/RTX	2.10 (-13.00-17.19)	0.78	0.81 (-16.61-18.23)	0.93
Prednisolone dose (per percentile)	1.84 (-1.81-5.48)	0.32	3.12 (-1.41-7.64)	0.18
Methylprednisolone dose (per 250 mg)	0.87 (-1.43-3.17)	0.46	0.04 (-2.67-2.75)	0.98

Analysis of 151 patients with complete treatment data and data on total hospital time.

CI, confidence interval; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; P-ANCA, perinuclear anti-neutrophil cytoplasmic antibodies; CRP, C-reactive protein; CYC/RTX, ≥2000 mg oral cyclophosphamide/≥1500 mg intravenous cyclophosphamide or rituximab

¹Multivariable analysis performed on 134 patients ²Data missing in five patients ³Data missing in five patients ⁴Data missing in seven patients